Astrazeneca

FromAstraZeneca ([email protected])
Subject (44)Third tozorakimab positive Phase III in COPD
Preheader (81)Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
Typography
Arial
Colors
Text Analysis
Body Words143
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px762 px
X-Spam Score-0.1
Preheader OptimizedNo
Timing
Day of WeekMonday
TimeAfternoon

Third tozorakimab positive Phase III in COPD

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
Third tozorakimab positive Phase III in COPD